MedTrace Logo

A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor

NCT00432783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2018-04-27

No results posted yet for this study

Summary

Pharmacologic boosting of protease inhibitors with ritonavir has become standard practice in antiretroviral therapy. Patients are instructed to take ritonavir at the same time as its accompanying protease inhibitor. However, ritonavir is unpopular with many patients because of its large size and because of the recommended need for refrigeration. This study will test the hypothesis that adherence to ritonavir is inferior to adherence to its accompanying protease inhibitor in patients receiving such therapy.

Conditions

  • HIV Infections

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Jonathan Shuter, MD · Montefiore Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00432783 on ClinicalTrials.gov